Drug Trial Radar · NCT00968812
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,452
Actual
Start
Sep 2009
Primary completion
Dec 2011
Study completion Jan 2013
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Aug 31, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
Conditions
- Diabetes Mellitus, Type 2
Interventions
GlimepirideDrug
Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
Canagliflozin (JNJ-28431754)Drug
Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
MetforminDrug
Metformin will be given orally at the protocol-specified dose for 104 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c From Baseline to Week 52Time frame: Day 1 (Baseline) and Week 52
Locations
138 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Calera, Alabama
Site not named
Gilbert, Arizona
Site not named
Mesa, Arizona
Site not named
Tucson, Arizona
Site not named
Jonesboro, Arkansas
Site not named
Buena Park, California
Site not named
Encinitas, California
Site not named
Fresno, California
Site not named
Lincoln, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
Westlake Village, California
Site not named
Chipley, Florida
Site not named
Marianna, Florida
Site not named
Oldsmar, Florida
Site not named
Orlando, Florida
Site not named
Augusta, Georgia
Site not named
Perry, Georgia
Site not named
Nampa, Idaho
Site not named
Chicago, Illinois
Site not named
Vernon Hills, Illinois
Site not named
Valparaiso, Indiana
Site not named
New Orleans, Louisiana
Site not named
Elkridge, Maryland
Site not named
Bloomfield Hills, Michigan
Site not named
Las Vegas, Nevada
Site not named
Canal Fulton, Ohio
Site not named
Gallipolis, Ohio
Site not named
Mason, Ohio
Site not named
Perrysburg, Ohio
Site not named
Tulsa, Oklahoma
Site not named
Yukon, Oklahoma
Site not named
Fleetwood, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Odessa, Texas
Site not named
Pearland, Texas
Site not named
San Antonio, Texas
Site not named
Danville, Virginia
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.